mHealth Wearables that Focus on Pain Relief
mHealth wearables that focus on pain relief are finding validation as an alternative to opioids.
SPR Therapeutics, the Cleveland-based developer of a digital health platform for treatment of acute and chronic pain, has received $10 million in grants and contracts from the US Department of Defense for three projects.
In addition, Waltham, Mass.-based NeuroMetrix has announced the publication of a study in the Journal of Pain and Relief that indicates its Quell wearable is helping people reduce pain, with corresponding improvements in activity and mood.
Quell Pain Relief
NeuroMetrix, meanwhile, is touting a study of more than 1,600 people with distal and proximal chronic pain who used the Quell wearable for at least 60 days. Those participating in the study transmitted their data – including changes in pain intensity and pain interference with sleep, activity, and mood on an 11-point numerical rating scale – to researchers for analysis at the beginning and end of the two-month project.
According to the study, participants used the device an average of 36 hours per week, and reported “statistically and clinically significant decreases in pain interference with activity and mood” and “a clinically significant decrease in pain intensity and less pain interference with sleep.”
“This study is the largest to demonstrate that fixed-site, high-frequency transcutaneous electrical nerve stimulation may have widespread effects beyond the site of stimulation, which is at the upper calf for Quell,” Shai N. Gozani, MD, PhD, the company’s President and CEO, said in a press release. “This is an important study for further establishing the Quell mechanism of action and is representative of our efforts to leverage the Quell Health Cloud to conduct sophisticated, large scale scientific and clinical research.”
Two years ago, NeuroMetrix launched a partnership with San Diego’s Scripps Translational Science Institute (now called the Scripps Research Translational Institute) to analyze how Quell might be used to help people living with cancer.
“This primary end point was chosen to provide a novel way for patients with cancer to have optimal pain control while reducing their overall opioid use,” SRTI officials said. “The study will also examine the potential benefits of Quell as a digital health intervention. The device integrates with a smartphone app that includes electronic pain tracking and provides objective feedback to the subject about their therapy utilization and sleep.”
We're here for you.or call 800.204.6577